Loading...
Loading...
A federal jury has found in favor of RyMed Technologies and against ICU Medical
ICUI in a closely-watched patent infringement case. The jury ruled that RyMed's InVision-Plus® with Neutral AdvantageTM technology products do not infringe on a patent held by ICU Medical.
The unanimous ruling by an eight-person jury means that ICU Medical can no longer make any claim that RyMed's products literally infringe on an in-force ICU Medical patent, said Dana Wm. Ryan, President, CEO and Chairman of the Board of RyMed Technologies.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in